Trials / Completed
CompletedNCT00540657
A Phase II Study of CCX282-B in Patients With Celiac Disease
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease
Detailed description
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCX282-B | 250mg capsule, twice daily, 13 weeks |
| DRUG | Placebo | Placebo capsule, twice daily, 13 weeks |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-06-01
- Completion
- 2008-07-01
- First posted
- 2007-10-08
- Last updated
- 2025-03-06
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00540657. Inclusion in this directory is not an endorsement.